| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Executive VP and CLO | Executive VP and CLO
1 company
Boulding Mark Elliott serves as an Executive VP and CLO at PTCT. Across recent SEC filings that breaks down to 0 buys and 166 sells. Those positions are worth an estimated $6.8M at current prices.
Historically, Boulding Mark Elliott's trades have earned a middling insider score of 56/100 across 50 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -12.1%.
The biggest single holding is PTCT (~$6.8M) as Executive VP and CLO. The recent filings there lean toward selling, a net 671,251 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 9, 2026 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sell10b5-1 | 6,347 | $77.06 | $489,080.53 | -5.4% | -8.6% | - | |
| Jan 7, 2026 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 6,618 | $77.31 | $511,641.42 | -5.3% | -9.9% | - | |
| Jan 5, 2026 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 2,266 | $75.55 | $171,191.98 | -1.8% | -10.2% | - | |
| Nov 17, 2025 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 3,397 | $76.05 | $258,332.14 | -3.2% | -8.5% | - | |
| Oct 7, 2025 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 3,375 | $63.43 | $214,091.17 | -3.1% | +20.1% | -1.1% | |
| Oct 6, 2025 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 24,921 | $65.75 | $1,638,548.63 | -19.3% | +18.5% | -1.7% | |
| Sep 12, 2025 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 47,249 | $61.18 | $2,890,586.51 | -31.3% | +23.5% | +8.1% | |
| Aug 15, 2025 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 2,813 | $48.58 | $136,655.54 | -2.6% | +53.5% | +46.9% | |
| May 16, 2025 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE | 2,812 | $46.13 | $129,716.88 | -2.6% | +5.8% | +55.3% | |
| Mar 12, 2025 | PTCT Ptc Therapeutics, Inc. | Executive VP and CLO | Sale+OE10b5-1 | 15,521 | $53.30 | $827,232.91 | -13.0% | -3.5% | +18.2% |